Global Pharmaceutical CMO Market to Grow at 7.15% CAGR Through 2032

[thorat Ketan]

The global Pharmaceutical Contract Manufacturing Market Size has witnessed significant growth over the past decade, and current trends suggest continued momentum. Valued at USD 161.76 billion in 2023, the market is projected to reach USD 300.34 billion by 2032, expanding at a Compound Annual Growth Rate (CAGR) of 7.15% during the forecast period of 2024–2032. This impressive growth trajectory highlights the increasing reliance of pharmaceutical companies on contract manufacturing organizations (CMOs) to enhance productivity, cost-efficiency, and scalability.

Market Overview

Pharmaceutical Contract Manufacturing involves outsourcing of drug manufacturing to third-party service providers. These CMOs offer a variety of services, ranging from formulation development and API (Active Pharmaceutical Ingredient) production to packaging and distribution.

Get Free Sample Report on Pharmaceutical Contract Manufacturing Market  

https://www.snsinsider.com/sample-request/4915

The increasing complexity of drug development, coupled with stringent regulatory requirements, has prompted pharmaceutical companies—especially small and mid-sized firms—to outsource manufacturing operations. This allows them to focus on core competencies such as research and development (R&D) while ensuring compliance and scalability through CMO partnerships.

Key Drivers of Market Growth

1. Rising Demand for Generics and Biologics
    Patent expirations of blockbuster drugs have led to a surge in the production of generics, fueling demand for cost-effective manufacturing solutions. Simultaneously, the rise of biologics and biosimilars is accelerating the need for specialized manufacturing capabilities, which CMOs are well-equipped to provide.
2. Cost Efficiency and Time Savings
    Establishing an in-house manufacturing unit is capital intensive. Pharmaceutical companies are increasingly outsourcing production to save on operational costs and reduce time-to-market, especially for clinical trials and new drug launches.
3. Stringent Regulatory Standards
    CMOs have robust infrastructures and are already compliant with global regulatory norms such as cGMP (current Good Manufacturing Practices). This enables faster product approval and reduces compliance risks for pharmaceutical companies.
4. Rapid Growth in Emerging Markets
    Contract manufacturing is gaining traction in developing economies like India, China, Brazil, and Mexico. These regions offer cost-effective labor, expanding healthcare infrastructure, and favorable government policies.
5. Expanding Therapeutic Applications
    With rising healthcare needs, especially in oncology, cardiology, infectious diseases, and CNS disorders, CMOs are diversifying their portfolios to include both small and large molecule drugs across various therapeutic areas.

Key Market Segments

By Service

• Pharmaceutical Manufacturing Services

• Pharmaceutical API Manufacturing Services

• Pharmaceutical FDF Manufacturing Services

• Drug Development Services

• Biologic Manufacturing Services

• Biologic API Manufacturing Services

• Biologic FDF Manufacturing Services

By End User

• Big Pharmaceutical Companies

• Small & Mid-Sized Pharmaceutical Companies

• Generic Pharmaceutical Companies

• Other

Competitive Landscape 

The market is highly fragmented, with leading players investing in facility expansion, strategic partnerships, and technological upgrades. Key players include:

1. Lonza Group
2. Catalent, Inc.
3. Thermo Fisher Scientific Inc.
4. Boehringer Ingelheim BioXcellence
5. Samsung Biologics
6. Recipharm AB
7. Famar Health Care Services
8. Jubilant Life Sciences Ltd.
9. Patheon N.V.
10. Pfizer CentreOne
11. And Others

These companies are focusing on strategic collaborations with biotech startups and pharma giants to enhance service portfolios and expand global reach.

Industry Trends & Opportunities

• Technological Advancements: Automation, AI, and IoT are being increasingly used in manufacturing processes, improving efficiency and reducing human error.
• Demand for Flexible Manufacturing: With the rise in personalized medicine and smaller batch sizes, CMOs are adapting to offer flexible production capabilities.
• Focus on Sustainability: Green manufacturing practices and eco-friendly packaging are becoming integral to gain regulatory and consumer trust.
• Biosimilars & Biologics: Growth in complex biologics has created a niche demand for specialized contract manufacturing services.
• COVID-19 Aftermath: The pandemic amplified the value of supply chain agility and CMO partnerships. These dynamics continue to shape the industry’s long-term outlook.

Challenges to Consider

Despite optimistic forecasts, the market faces some hurdles:

• Regulatory Complexity: Varying global regulations may complicate cross-border manufacturing.
• Quality Assurance: Ensuring consistent quality across diverse product categories and geographies remains a critical challenge.
• Supply Chain Disruptions: Political instability, trade barriers, and natural disasters can impact timely delivery.

Nonetheless, players who invest in compliance, digitalization, and capacity-building are poised to turn these challenges into strategic opportunities.

Recent Developments

• In 2024, Catalent expanded its biologics facility in Indiana, USA, to meet increasing demand from biotech clients.
• Samsung Biologics partnered with several mRNA-focused biotech firms to provide end-to-end CDMO services.
• Lonza Group announced a USD 1 billion investment in its Swiss facility to support high-potency APIs and next-generation biologics.

These strategic moves reflect the dynamic evolution and future-readiness of key players in the global pharmaceutical contract manufacturing landscape.

Future Outlook

The Pharmaceutical Contract Manufacturing Market is set to enter a transformative phase over the next decade. As the healthcare industry pivots toward advanced therapies, precision medicine, and complex biologics, the demand for high-end contract manufacturing services will surge.

The outlook remains bullish, with USD 300.34 billion in expected revenue by 2032. Companies that embrace innovation, strengthen regulatory frameworks, and forge long-term collaborations will emerge as market leaders.

 About US

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:

Jagney Dave - Vice President of Client Engagement

Phone: [phone] (US) | [phone] (UK).